Rational combinations of immunotherapy with radiotherapy in ovarian cancer
Rational combinations of immunotherapy with radiotherapy in ovarian cancer
复制标题
DOI：
10.1016/s1470-2045(19)30401-2
复制
发表时间：
2019-08-01
期刊：
影响因子：
51.1
通讯作者：
Coukas, George
中科院分区：
文献类型：
--
作者：
Herrera, Fernando G.;Irving, Melita;Coukas, George
除了在姑息治疗中的应用外，由于全身化疗的有效性和毒性较低，放射治疗在卵巢癌的治疗中已基本被放弃。新的数据显示，放射疗法与免疫疗法在控制或根除癌症方面具有协同作用。在几种肿瘤模型中，不同剂量的大分割放疗已显示出诱导免疫原性细胞死亡和原位疫苗接种。然而，低于2戈伊的剂量也可以重新编程肿瘤微环境。本系列文章讨论了过去和现在放射治疗卵巢癌的应用，以及放射治疗可以动员抗癌免疫的机制。我们提供了将免疫疗法与放射疗法相结合治疗卵巢癌的临床前和临床数据，并提供了临床开发路线图，以指导下一代针对这种疾病的联合策略的临床试验。
Except for its use in palliative care, radiotherapy has been largely abandoned in the management of ovarian cancer because of the recognised efficacy and lower toxicity of systemic chemotherapy compared with radiotherapy. New data have emerged that show synergy of radiotherapy with immunotherapy to control or eradicate cancer. Different doses of hypofractionated radiotherapy have been shown to induce immunogenic cell death and in-situ vaccination in several tumour models. However, doses less than 2 Gy can also reprogramme the tumour microenvironment. This Series paper discusses the past and present use of radiotherapy for ovarian cancer, and the mechanisms by which radiotherapy can mobilise anticancer immunity. We provide emerging preclinical and clinical data for combining immunotherapy with radiotherapy for ovarian cancer treatment and offer a clinical development roadmap to guide the next generation of clinical trials for this combination strategy for this disease.